Larry Biegelsen's Stock Ratings

Wells Fargo Analyst

Larry Biegelsen is an analyst at Wells Fargo. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/16/2024

Overall Average Return

14.3%

Smart Score

74.6%

Overall Average Return Percentile

69th

Number of Ratings

138
Buy NowGet Alert
05/15/2024ALCBuy Now
Alcon
$89.744.75%$89 → $94MaintainsOverweightGet Alert
05/07/2024RXSTBuy Now
RxSight
$62.269.22%$61 → $68MaintainsOverweightGet Alert
05/03/2024TNDMBuy Now
Tandem Diabetes Care
$46.936.54%$45 → $50MaintainsOverweightGet Alert
05/02/2024GKOSBuy Now
Glaukos
$110.41-0.37%$103 → $110MaintainsOverweightGet Alert
05/01/2024SYKBuy Now
Stryker
$333.9814.08%$364 → $381MaintainsOverweightGet Alert
05/01/2024NARIBuy Now
Inari Medical
$46.3081.43%$100 → $84MaintainsOverweightGet Alert
04/29/2024TNDMBuy Now
Tandem Diabetes Care
$46.93-4.11%$21 → $45UpgradeEqual-Weight → OverweightGet Alert
04/26/2024EWBuy Now
Edwards Lifesciences
$90.119.87%$94 → $99MaintainsOverweightGet Alert
04/25/2024BSXBuy Now
Boston Scientific
$74.559.99%$72 → $82MaintainsOverweightGet Alert
04/08/2024NVROBuy Now
Nevro
$11.1725.34%$17 → $14MaintainsEqual-WeightGet Alert
04/03/2024NVCRBuy Now
NovoCure
$22.2588.76%$49 → $42MaintainsOverweightGet Alert
03/22/2024HYPRBuy Now
Hyperfine
$0.8881.2%$2.1 → $1.6MaintainsEqual-WeightGet Alert
02/23/2024LUNGBuy Now
Pulmonx
$9.0554.7%$16 → $14DowngradeOverweight → Equal-WeightGet Alert
02/22/2024GKOSBuy Now
Glaukos
$110.41-6.71%$83 → $103MaintainsOverweightGet Alert
02/22/2024LUNGBuy Now
Pulmonx
$9.0576.8%$15 → $16MaintainsOverweightGet Alert
02/22/2024BLCOBuy Now
Bausch & Lomb
$15.2450.92%$21 → $23MaintainsOverweightGet Alert
02/16/2024SWAVBuy Now
ShockWave Medical
$330.88-36.53%$200 → $210MaintainsEqual-WeightGet Alert
02/02/2024EWBuy Now
Edwards Lifesciences
$90.114.32% → $94UpgradeEqual-Weight → OverweightGet Alert
02/01/2024BSXBuy Now
Boston Scientific
$74.55-3.42%$70 → $72MaintainsOverweightGet Alert
01/31/2024SYKBuy Now
Stryker
$333.988.99%$336 → $364MaintainsOverweightGet Alert
01/19/2024ISRGBuy Now
Intuitive Surgical
$396.434.94%$363 → $416MaintainsOverweightGet Alert
01/10/2024AXNXBuy Now
Axonics
$67.674.92%$68 → $71DowngradeOverweight → Equal-WeightGet Alert
12/29/2023BSXBuy Now
Boston Scientific
$74.55-16.83%$62 → $62ReiteratesOverweight → OverweightGet Alert
12/13/2023BSXBuy Now
Boston Scientific
$74.55-16.83%$59 → $62MaintainsOverweightGet Alert
12/13/2023DXCMBuy Now
DexCom
$131.003.82%$110 → $136MaintainsOverweightGet Alert
12/13/2023INSPBuy Now
Inspire Medical Systems
$159.0317.59% → $187DowngradeOverweight → Equal-WeightGet Alert
12/13/2023JNJBuy Now
Johnson & Johnson
$154.255.67%$170 → $163DowngradeOverweight → Equal-WeightGet Alert
12/13/2023RXSTBuy Now
RxSight
$62.26-32.54% → $42UpgradeEqual-Weight → OverweightGet Alert
12/05/2023IARTBuy Now
Integra Lifesciences
$27.4978.25%$40 → $49UpgradeEqual-Weight → OverweightGet Alert
11/08/2023INSPBuy Now
Inspire Medical Systems
$159.0354.06%$330 → $245MaintainsOverweightGet Alert

Recent Analyst Stock Rating News

Decoding 18 Analyst Evaluations For Boston Scientific
Assessing Nevro: Insights From 9 Financial Analysts
Assessing Edwards Lifesciences: Insights From 11 Financial Analysts
Unveiling 8 Analyst Insights On NovoCure
Key Takeaways From Boston Scientific Analyst Ratings
Johnson & Johnson Likely To Report Higher Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Johnson & Johnson (NYSE: JNJ) is set to release earnings results for its first quarter before the opening bell on April 16, 2024.
What Analysts Are Saying About Edwards Lifesciences Stock
Analyst Ratings For Glaukos
Unveiling 13 Analyst Insights On Boston Scientific
Navigating 6 Analyst Ratings For Pulmonx
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free